iRhythm Technologies (IRTC) Stock Forecast & Price Target

iRhythm Holdings is viewed positively because its Zio platform is supported by a differentiated, FDA-cleared and CE-marked wearable and cloud analytics stack that can help clinicians diagnose arrhythmias faster and more efficiently than legacy monitoring methods. The company has also shown durable operating momentum, with revenue of $224.2M up 20.1% year over year, gross margin of 72.8%, and adjusted EBITDA of $43.3M, while management raised 2026 revenue guidance and expects continued profitability improvement. Additional confidence comes from the VitalConnect acquisition, which is expected to broaden its MCT reach, strengthen growth in 2027, and support 70%+ gross margin and a 15% adjusted EBITDA margin.

iRhythm Holdings is viewed negatively because its growth path appears vulnerable to slower sales execution, intensifying competition, and reimbursement pressure, all of which could compress both revenue growth and profitability improvement. The cited bear-case assumes growth slows to the low-teens, and the company also faces execution risks from product launches such as ZioAT, potential FDA Warning Letter or CID-related regulatory outcomes, and the possibility of an additional equity offering that could dilute shareholders. While broader scale and payor coverage could support some upside, uncertainty around commercial traction, expanded market opportunities like asymptomatic AF, and changes in CMS MA risk-adjust model dynamics leaves the fundamental outlook fragile.